Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review

Autor: Da-Ming Kong, Wen-Jun Chen, Liang Li
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Oncology
Abiraterone Acetate
030232 urology & nephrology
ECOG Performance Status
Docetaxel
urologic and male genital diseases
lcsh:RC870-923
Severity of Illness Index
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
castration-resistant prostate cancer
030219 obstetrics & reproductive medicine
Hazard ratio
eastern cooperative oncology group performance status
gleason score
meta-analysis
overall survival
Abiraterone acetate
General Medicine
Prognosis
Eastern Cooperative Oncology Group performance status
Survival Rate
Prostatic Neoplasms
Castration-Resistant
Cabazitaxel
Benzamides
Taxoids
Original Article
Radium
medicine.drug
medicine.medical_specialty
Urology
Antineoplastic Agents
03 medical and health sciences
Internal medicine
Nitriles
Phenylthiohydantoin
medicine
Humans
Gleason score
neoplasms
Proportional Hazards Models
Taxane
Performance status
Tissue Extracts
business.industry
medicine.disease
lcsh:Diseases of the genitourinary system. Urology
chemistry
Neoplasm Grading
business
Zdroj: Asian Journal of Andrology, Vol 23, Iss 2, Pp 163-169 (2021)
Asian Journal of Andrology
ISSN: 1745-7262
Popis: Eastern Cooperative Oncology Group (ECOG) performance status and Gleason score are commonly investigated factors for overall survival (OS) in men with castration-resistant prostate cancer (CRPC). However, there is a lack of consistency regarding their prognostic or predictive value for OS. Therefore, we performed this meta-analysis to assess the associations of ECOG performance status and Gleason score with OS in CRPC patients and compare the two markers in patients under different treatment regimens or with different chemotherapy histories. A systematic literature review of monotherapy studies in CRPC patients was conducted in the PubMed database until May 2019. The data from 8247 patients in 34 studies, including clinical trials and real-world data, were included in our meta-analysis. Of these, twenty studies reported multivariate results and were included in our main analysis. CRPC patients with higher ECOG performance statuses (≥ 2) had a significantly increased mortality risk than those with lower ECOG performance statuses (
Databáze: OpenAIRE
Externí odkaz: